No Data
No Data
Shanghai Yizhong Pharmaceutical Co., Ltd.'s 2024 interim report (corrected version).
Summary of the 2024 interim report (revised version) of Shanghai Yizhong Pharmaceutical Co., Ltd.
Correction Announcement on the 2024 Interim Report of Yizhong Pharmaceuticals Co., Ltd. in Shanghai.
Shanghai Yizhong's 2024 semi-annual report.
Shanghai Yizhong Pharmaceutical Co., Ltd. 2024 Interim Report Summary
Shanghai Yizhong (688091.SH): net income of 345.089 million yuan in the first half of the year, a 66.85% decrease compared to the same period last year.
On August 7th, GeLongHui reported the semi-annual report of Shanghai Yizhong (688091.SH), with a revenue of 0.12 billion yuan, a year-on-year decrease of 39.17%, a net income of 34.5089 million yuan, a year-on-year decrease of 66.85%, and a non-recurring net income of 33.16 million yuan, a year-on-year decrease of 62.85%, with a basic earnings per share of 0.17 yuan. The company's core product, "docetaxel injection polymer micelle (Zisheng R)" was selected as the first batch project of the national "major new drug creation" science and technology major project in the "Thirteenth Five-Year Plan". The product was classified as a Class 2.2 drug by the National Medical Products Administration in October 2021 (both at home and abroad not yet marketed).
No Data